查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1968527

医药知识管理软体市场－全球产业规模、份额、趋势、机会、预测：按部署方式、组织规模、地区和竞争格局划分，2021-2031年

Pharma Knowledge Management Software Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented, By Deployment, By Organization Size, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球医药知识管理软体市场预计将从 2025 年的 56.2 亿美元大幅成长至 2031 年的 159.4 亿美元，复合年增长率达 18.98%。

这些平台作为专门的数位系统，旨在收集、整理和搜寻贯穿整个药物研发生命週期的专有讯息，从药物发现的早期阶段到最终的商业化。这些系统对于保护智慧财产权和确保严格的监管合规至关重要，同时也促进了地理位置分散的研究团队之间的无缝协作。推动这些系统成长要素包括：缩短新治疗方法上市时间的迫切需求、对审核文件的需求，以及防止因员工流动和组织结构调整而导致的知识流失。

市场概览
预测期 2027-2031
市场规模：2025年 56.2亿美元
市场规模：2031年 159.4亿美元
复合年增长率：2026-2031年 18.98%
成长最快的细分市场 云
最大的市场 北美洲

然而，市场面临许多挑战，包括资料碎片化和非结构化遗留资讯的氾滥。对许多製药公司而言，将孤立的资料孤岛整合到统一的储存库中，在技术和文化层面都是一项艰鉅的任务。根据皮斯托亚联盟（Pistoia Alliance）预测，到2024年，52%的生命科学专业人士将认为低品质且管理不善的资料集是采用先进研发技术的主要障碍。这项数据凸显了製药公司在将庞大的资讯檔案整合为可存取且可操作的数据方面所面临的巨大挑战。

市场驱动因素

基于云端和人工智慧的知识解决方案的整合正在从根本上改变製药公司管理其智慧财产权的方式。随着企业从孤立的旧有系统转向互联互通的数位生态系统，这些先进技术正在促进即时数据存取和决策改进。这项转变对于管理现代研发产生的大量非结构化资料至关重要，并能帮助科学家快速发现和整合全球团队的资讯。据皮斯托亚联盟（Pistoia Alliance）称，截至2025年9月，77%的生命科学实验室计划在未来两年内使用人工智慧技术，这表明知识管理基础设施正朝着自动化和智慧化的方向显着转变。

同时，随着加速药物研发和缩短上市时间的压力日益增大，企业被迫优化数据管道以实现雄心勃勃的商业目标。鑑于专利生命週期有限且研发成本高昂，知识管理软体是简化工作流程和避免重复研究的关键基础。这种推动快速创新的动力在主要产业领导者设定的高生产力目标中显而易见。例如，罗氏在2025年宣布了一项策略目标，即到2029年推出20种突破性新疗法。为了维持这种快速创新，大量资金正涌入数位化和生技领域。 2025年10月，赛诺菲将企业创业投资基金增加至14亿美元，专门用于投资人工智慧和数位健康技术。

市场挑战

资料片段化和非结构化遗留资讯的氾滥是全球医药知识管理软体市场成长的主要障碍。製药公司在整合数据方面常常面临挑战，这些数据分散在孤立的系统中，并在整个药物研发过程中以不一致的格式储存。这种缺乏连接性阻碍了统一储存库的创建，而统一储存库对于知识管理平台的成功实施至关重要。当关键研究数据仍然局限于不同的系统，缺乏标准化的框架时，由于需要手动采集数据，企业将面临严重的营运延误和成本增加，从而有效地抵消了这些软体解决方案本应带来的效率提升。

这些持续存在的技术壁垒限制了供应商的潜在市场，因为潜在客户不愿意投资那些难以与现有基础设施整合的平台。无法有效协调各种数据来源阻碍了数位转型进程。根据皮斯托亚联盟（Pistoia Alliance）预测，到2024年，60%的生命科学专业人士将资料互通性和整合能力的不足视为采用以资料为中心的技术的主要障碍。这项数据凸显了市场中一个显着的摩擦点：建构遗留资料这项资源密集型任务迫使企业转移软体部署预算，转而关注其他方面，最终导致整体市场成长放缓。

市场趋势

将生成式人工智慧应用于自动化内容合成正在重塑知识管理系统，使其从被动的储存设备转变为主动的智慧引擎。製药公司正日益利用这些功能自动产生复杂的文檔，例如临床试验报告、安全性总结和监管申报文件，从而减少人工工作量并最大限度地减少人为错误。这一趋势透过使用大规模语言模型从海量历史资料中提取和整合相关信息，直接解决了监管文件编制中的瓶颈问题。根据 2024 年 7 月 PharmaTimes 的报告《GenAI 走出困境》，53% 的监管负责人认识到，他们迫切需要利用人工智慧进行资讯摘要，以简化这些繁琐的文件创建工作。

同时，语意搜寻和企业知识图谱的采用正成为支援这些先进人工智慧工作流程的结构性必要条件。为了确保生成模型能够提供准确可靠的输出，企业正从非结构化资料湖转向语意连结的知识图谱，从而确保资料的上下文关联性和可追溯性。这项转变的驱动力在于，需要使专有资料在整个药物研发生命週期中都符合 FAIR 原则——即可找到、可存取、可互通和可重复使用。 Pistoia Alliance 于 2024 年 9 月进行的「2024 年未来实验室全球调查」凸显了这种架构转变的迫切性，其中 38% 的生命科学受访者认为非 FAIR 数据是有效采用人工智慧技术的主要障碍。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球医药知识管理软体市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 部署方式（本机部署、云端部署、混合式部署）
    • 依组织规模（中小企业、大型企业）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美医药知识管理软体市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲医药知识管理软体市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区医药知识管理软体市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东与非洲医药知识管理软体市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲医药知识管理软体市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球医药知识管理软体市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • SAP SE
  • Oracle Corporation
  • Dassault Systemes SE
  • ArisGlobal LLC
  • MasterControl Inc.
  • Accenture plc
  • IQVIA Holdings Inc.
  • Veeva Systems Inc.
  • Honeywell International Inc.
  • Sparta Systems Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 26616

The Global Pharma Knowledge Management Software Market is projected to expand significantly, rising from USD 5.62 Billion in 2025 to USD 15.94 Billion by 2031, reflecting a compound annual growth rate of 18.98%. These platforms serve as specialized digital systems designed to capture, organize, and retrieve proprietary information throughout the drug development lifecycle, spanning from initial discovery to final commercialization. Critical for safeguarding intellectual property and maintaining strict regulatory compliance, these systems also enable seamless collaboration among geographically dispersed research teams. Key growth factors include the urgent need to speed up the time-to-market for new treatments, the requirement for audit-ready documentation, and the necessity to prevent knowledge loss caused by employee turnover or organizational restructuring.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.62 Billion
Market Size 2031USD 15.94 Billion
CAGR 2026-203118.98%
Fastest Growing SegmentCloud
Largest MarketNorth America

However, the market faces a substantial obstacle in the form of data fragmentation and the abundance of unstructured legacy information. Merging isolated data silos into a cohesive repository presents a difficult technical and cultural challenge for many pharmaceutical enterprises. According to the Pistoia Alliance, in 2024, 52% of life science experts pinpointed low-quality and poorly curated datasets as the primary hindrance to adopting advanced R&D technologies. This statistic highlights the significant struggle pharmaceutical companies face in harmonizing their extensive information archives into accessible and actionable intelligence.

Market Driver

The increasing integration of cloud-based and AI-powered knowledge solutions is fundamentally transforming how pharmaceutical companies manage their intellectual property. As organizations move away from isolated legacy systems toward interconnected digital ecosystems, these advanced technologies are facilitating real-time data access and improved decision-making. This transition is essential for managing the vast amounts of unstructured data produced by modern R&D, enabling scientists to quickly locate and synthesize information across global teams. According to the Pistoia Alliance, in September 2025, 77% of life sciences laboratories anticipate using artificial intelligence technologies within the next two years, indicating a clear shift toward automated and intelligent knowledge management infrastructures.

Simultaneously, the pressure to accelerate drug discovery and shorten time-to-market is compelling companies to refine their data pipelines to achieve aggressive commercial goals. Given that patent lifecycles are limited and development costs are high, knowledge management software serves as a crucial backbone for streamlining workflows and preventing duplicative research. This drive for rapid innovation is illustrated by major industry leaders setting high output targets; for instance, Roche announced in 2025 a strategic goal to launch 20 new breakthrough therapies by 2029. To sustain such high-velocity innovation, significant capital is flowing into digital and biotech advancements, as seen in October 2025 when Sanofi increased its corporate venture capital fund to $1.4 billion to specifically invest in artificial intelligence and digital health technologies.

Market Challenge

The prevalence of data fragmentation and unstructured legacy information stands as a major obstacle to the growth of the global pharma knowledge management software market. Pharmaceutical companies often face difficulties in consolidating proprietary data that is dispersed across isolated silos and stored in inconsistent formats throughout the drug development process. This lack of connectivity hinders the establishment of a unified repository, which is essential for the successful implementation of knowledge management platforms. When vital research data remains locked in disparate systems without a standardized framework, organizations encounter significant operational delays and higher costs due to manual data retrieval, effectively negating the efficiency benefits these software solutions are meant to deliver.

These persistent technical barriers restrict the addressable market for vendors, as potential customers are reluctant to invest in platforms that struggle to integrate with their current infrastructure. The failure to effectively harmonize various data sources halts digital transformation efforts. According to the Pistoia Alliance, in 2024, 60% of life science professionals identified the lack of data interoperability and integration capabilities as a leading impediment to adopting data-centric technologies. This statistic underscores a critical market friction, where the resource-heavy task of structuring legacy data compels enterprises to redirect budget and attention away from software acquisition, thereby slowing overall market expansion.

Market Trends

The integration of Generative AI for Automated Content Synthesis is reshaping knowledge management systems, elevating them from passive storage units to active intelligence engines. Pharmaceutical entities are increasingly leveraging these capabilities to automate the generation of complex documents, such as clinical study reports, safety summaries, and regulatory submissions, which reduces manual workload and minimizes human error. This trend directly tackles the bottleneck of regulatory writing by using large language models to extract and synthesize pertinent findings from extensive historical data. According to PharmaTimes in July 2024, the 'GenAI out of the bottle' report noted that 53% of regulatory professionals recognized a specific need to use artificial intelligence for information summarization to streamline these labor-intensive documentation tasks.

Concurrently, the adoption of Semantic Search and Enterprise Knowledge Graphs is becoming a structural necessity to support these advanced AI workflows. To ensure generative models deliver accurate and reliable outputs, companies are moving from unstructured data lakes to semantically linked knowledge graphs that ensure data contextualization and traceability. This evolution is driven by the need to make proprietary data Findable, Accessible, Interoperable, and Reusable (FAIR) throughout the drug development lifecycle. According to the Pistoia Alliance's 'Lab of the Future 2024 Global Survey' in September 2024, 38% of life science respondents identified data that fails to adhere to FAIR principles as a major hurdle to the effective implementation of AI technologies, highlighting the urgency of this architectural shift.

Key Market Players

  • SAP SE
  • Oracle Corporation
  • Dassault Systemes SE
  • ArisGlobal LLC
  • MasterControl Inc.
  • Accenture plc
  • IQVIA Holdings Inc.
  • Veeva Systems Inc.
  • Honeywell International Inc.
  • Sparta Systems Inc.

Report Scope

In this report, the Global Pharma Knowledge Management Software Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharma Knowledge Management Software Market, By Deployment

  • On-Premises
  • Cloud
  • Hybrid

Pharma Knowledge Management Software Market, By Organization Size

  • Small & Medium Enterprises
  • Large Enterprises

Pharma Knowledge Management Software Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharma Knowledge Management Software Market.

Available Customizations:

Global Pharma Knowledge Management Software Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharma Knowledge Management Software Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Deployment (On-Premises, Cloud, Hybrid)
    • 5.2.2. By Organization Size (Small & Medium Enterprises, Large Enterprises)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Pharma Knowledge Management Software Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Deployment
    • 6.2.2. By Organization Size
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pharma Knowledge Management Software Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Deployment
        • 6.3.1.2.2. By Organization Size
    • 6.3.2. Canada Pharma Knowledge Management Software Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Deployment
        • 6.3.2.2.2. By Organization Size
    • 6.3.3. Mexico Pharma Knowledge Management Software Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Deployment
        • 6.3.3.2.2. By Organization Size

7. Europe Pharma Knowledge Management Software Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Deployment
    • 7.2.2. By Organization Size
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pharma Knowledge Management Software Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Deployment
        • 7.3.1.2.2. By Organization Size
    • 7.3.2. France Pharma Knowledge Management Software Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Deployment
        • 7.3.2.2.2. By Organization Size
    • 7.3.3. United Kingdom Pharma Knowledge Management Software Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Deployment
        • 7.3.3.2.2. By Organization Size
    • 7.3.4. Italy Pharma Knowledge Management Software Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Deployment
        • 7.3.4.2.2. By Organization Size
    • 7.3.5. Spain Pharma Knowledge Management Software Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Deployment
        • 7.3.5.2.2. By Organization Size

8. Asia Pacific Pharma Knowledge Management Software Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Deployment
    • 8.2.2. By Organization Size
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pharma Knowledge Management Software Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Deployment
        • 8.3.1.2.2. By Organization Size
    • 8.3.2. India Pharma Knowledge Management Software Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Deployment
        • 8.3.2.2.2. By Organization Size
    • 8.3.3. Japan Pharma Knowledge Management Software Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Deployment
        • 8.3.3.2.2. By Organization Size
    • 8.3.4. South Korea Pharma Knowledge Management Software Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Deployment
        • 8.3.4.2.2. By Organization Size
    • 8.3.5. Australia Pharma Knowledge Management Software Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Deployment
        • 8.3.5.2.2. By Organization Size

9. Middle East & Africa Pharma Knowledge Management Software Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Deployment
    • 9.2.2. By Organization Size
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pharma Knowledge Management Software Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Deployment
        • 9.3.1.2.2. By Organization Size
    • 9.3.2. UAE Pharma Knowledge Management Software Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Deployment
        • 9.3.2.2.2. By Organization Size
    • 9.3.3. South Africa Pharma Knowledge Management Software Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Deployment
        • 9.3.3.2.2. By Organization Size

10. South America Pharma Knowledge Management Software Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Deployment
    • 10.2.2. By Organization Size
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pharma Knowledge Management Software Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Deployment
        • 10.3.1.2.2. By Organization Size
    • 10.3.2. Colombia Pharma Knowledge Management Software Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Deployment
        • 10.3.2.2.2. By Organization Size
    • 10.3.3. Argentina Pharma Knowledge Management Software Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Deployment
        • 10.3.3.2.2. By Organization Size

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pharma Knowledge Management Software Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. SAP SE
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Oracle Corporation
  • 15.3. Dassault Systemes SE
  • 15.4. ArisGlobal LLC
  • 15.5. MasterControl Inc.
  • 15.6. Accenture plc
  • 15.7. IQVIA Holdings Inc.
  • 15.8. Veeva Systems Inc.
  • 15.9. Honeywell International Inc.
  • 15.10. Sparta Systems Inc.

16. Strategic Recommendations

17. About Us & Disclaimer